Novavax Plans to Cut $50 Million in Costs, COVID-19 Vaccine Remains Only Marketed Product

by Vandana Singh, Benzinga Editor
April 13, 2023 7:03 AM | 2 min read |
  • Novavax Inc's NVAX CEO, newly appointed CEO John Jacobs, said the company would cut about $50 million in costs in Q1 of 2023 and plans further cuts.
  • "We're looking at everything from buildings, leases, land, headcount, and contractors, every aspect of our company and the way we work," Jacobs said in an interview with Reuters.
  • Jacobs also said the company is in regular talks with the FDA over the potential design of its 2023 COVID-19 booster shot and believes Novavax will have a new shot ready in time for the fall.
  • The company appointed John Jacobs, President & CEO following the retirement of Stanley Erck, who served as President & CEO for 12 years.
  • Also Read: FDA's Regulatory Delay is The Reason For Novavax, Lucira Health's Failure
  • Novavax's COVID-19 vaccine is its only marketed product after 35 years in business, the report added.
  • The CEO added that the company did not expect to launch its individual flu vaccine this year and will focus on the COVID vaccine.
  • Jacobs said Novavax would seek funding for its COVID/influenza combination shot, depending on whether the upcoming data is positive.
  • In February, when the company released its fiscal 2022 earnings, it said, "substantial doubt exists regarding our ability to continue as a going concern through one year from the date that these financial statements are issued."
  • Novavax's Q4 revenue increased 61% year-over-year to $357 million, which missed average analyst estimates of $383.14 million.
  • In its 10K filing, the company said the U.S. government did not extend its agreement with Novavax beyond December 2023, putting some of the remaining $416 million in that deal at risk.
  • Novavax also said that depending on the outcome of its arbitration with Gavi, it could be required to refund all or a portion of the $697.4 million it received from the group.
  • Price Action: NVAX shares are up 1.44% at $9.16 during the premarket session on the last check Thursday.
  • Photo by Jernej Furman via Flickr
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!